Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
103 hedge funds and large institutions have $353M invested in Albireo Pharma Inc in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 21 closing their positions.
188% more call options, than puts
Call options by funds: $2.49M | Put options by funds: $863K
9% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 34
6% less funds holding
Funds holding: 110 → 103 (-7)
19% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 21
29% less capital invested
Capital invested by funds: $497M → $353M (-$144M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.6M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$10.4M |
| 3 |
CC
Chicago Capital
Chicago,
Illinois
|
+$8.96M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.13M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$6.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$5.79M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.06M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.73M |
| 4 |
SCM
Sio Capital Management
New York
|
-$2.27M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.19M |
ALBO Hedge Fund Activity: Q2 2022 in Review
103 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2022, worth a combined $353M — down 29% from $497M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ALBO and 17 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 37 added.
The largest buyer was State Street, adding an estimated $13.6M. The largest seller was OrbiMed, exiting entirely with an estimated $5.79M sold.
- 103 institutional investors held Albireo Pharma Inc (ALBO) as of Q2 2022, down from 110 in Q1 2022.
- Funds reported $353M of Albireo Pharma Inc stock for Q2 2022, down 29% quarter-over-quarter.
- 17 funds opened new Albireo Pharma Inc positions in Q2 2022 and 21 closed out, a net change of -4 holders.
- The largest Albireo Pharma Inc buyer in Q2 2022 was State Street, an estimated $13.6M added.
- The largest Albireo Pharma Inc seller in Q2 2022 was OrbiMed, an estimated $5.79M sold.
Based on aggregated 13F filings for Q2 2022.